Adagrasib bests docetaxel in pretreated KRAS G12C-NSCLC, adding nivolumab to tivozanib in metastatic RCC underwhelms, and T-DXd shows improvement in HER2+ breast cancer with brain metastases.
Morgan Bayer
Morgan Bayer is an assistant editor for Targeted Oncology and Targeted Therapies in Oncology.
Articles by Morgan Bayer
Combination therapies in CLL are generating excitement with ongoing trials that could expand standard practice for the future.
The HIMALAYA study showed that the combination of tremelimumab and durvalumab significantly improved overall survival in patients with hepatocellular carcinoma.
The FDA granted IBI363 fast track status for melanoma and approved a ready-to-use subcutaneous bortezomib for MM and MCL. We also cover new data highlighting the efficacy of lenvatinib/pembrolizumab in nccRCC, cost-effectiveness of TKIs for CML, and innovative immunotherapies for T-cell malignancies.
Test your knowledge on the current pulse of oncology including FDA updates and breaking data with our Targeted Pulse Quiz.
The study found that lenvatinib continued to demonstrate improved efficacy in patients with radioiodine-refractory differentiated thyroid cancer.
The digital twin trial arm demonstrated a 52.7% overall response rate at 6 months for prednisone in chronic GVHD, aligning with real-world data.
Pembrolizumab plus concurrent chemoradiotherapy demonstrated a higher progression-free survival rate than placebo plus concurrent chemoradiotherapy for patients with high-risk, locally advanced cervical cancer in the East Asia subgroup of the phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study.
Test your knowledge on the current pulse of oncology including FDA updates and breaking data with our Targeted Pulse Quiz.
IL-21-engineered NK cells offer superior safety and long-term control for glioblastoma, Merck halted 2 phase 3 KEYNOTE trials of pembrolizumab, and the MonumenTAL-1 trial data is discussed.
There are remaining gaps in papillary renal cell carcinoma that data from 3 pending trials hope to fill.
Test your knowledge on the current pulse of oncology including FDA updates and breaking data with our Targeted Pulse Quiz.
The FDA fast-tracked BGB-16673 for advanced CLL/SLL, Ticiana Leal, MD, compares lurbinectedin and topotecan for extensive-stage SCLC, and sonrotoclax and zanubrutinib show improved results in early CLL/SLL trials.
T-DXd receives FDA breakthrough therapy designation for HR+/HER2-low breast cancer and real-world data confirms brexu-cel’s efficacy in relapsed/refractory B-cell ALL. A New AI-based study enrolls first patient, strengths and weakness in multiple myeloma treatment are examined, and tafasitamab combination scores in FL.
Test your knowledge on the current pulse of oncology including FDA updates and breaking data with our Targeted Pulse Quiz.
Test your knowledge on the current pulse of oncology including FDA updates and breaking data with our Targeted Pulse Quiz.
Apalutamide offers a quicker, deeper PSA response vs enzalutamide in mCSPC and the SENTRY study supports SOC combination therapy for myelofibrosis. We also cover integrative oncology, which has been shown to reduce cancer-related anxiety and depression and we explore vorasidenib’s FDA approval in glioma treatment.
FDA approves afami-cel for advanced synovial sarcoma and dostarlimab is now approved for all advanced endometrial cancers. In addition, buprenorphine offers improved pain management for bone marrow transplant patients, subcutaneous amivantamab reduces AEs, and SRS offers benefits over WBRT for SCLC.
Test your knowledge on the current pulse of oncology including FDA updates and breaking data with our Targeted Pulse Quiz.
The FDA’s ODAC mandates phase assessments for NSCLC trials, dendritic cell immunotherapy shows improved survival in pancreatic cancer, and a new blood test for colorectal cancer receives FDA approval. In addition, pembrolizumab plus neoadjuvant chemo proves effective in unresectable HGSC and THIO-cemiplimab combo shows lower toxicity in advanced NSCLC.
Test your knowledge on the current pulse of oncology including FDA updates and breaking data with our Targeted Pulse Quiz.
Test your knowledge on the current pulse of oncology including FDA updates and breaking data with our Targeted Pulse Quiz.
The FDA cleared ADC, ZW191, for difficult-to-treat cancers, immunotherapy showed varied efficacy in angiosarcomas, and the cabozantinib/nivolumab combination demonstrated promising results in RCC. We also cover FDA setbacks for botensilimab/balstilimab in mCRC, and the lackluster effects of nivolumab/tivozanib for RCC.
Test your knowledge on the current pulse of oncology including FDA updates and breaking data with our Targeted Pulse Quiz.
Amivantamab/lazertinib trumps osimertinib in lung cancer treatment, promising results with nivolumab in dMMR in gynecologic cancers, and Curium’s lutetium-177 submission for SSTR-positive GEP-NETs are featured. Regarding lung cancer, we also cover valuable insights on immunotherapy combinations and breakthrough treatments presented at ASCO.
A handful of positive news highlights new treatments: Orca-T’s superior outcomes in hematologic malignancies, 225Ac-FL-020 receiving fast track for prostate cancer, the addition of glofitamab leading to greater efficacy in DLBCL, and real-world data demonstrating lenvatinib’s effectiveness in RAI-refractory thyroid cancer.
Test your knowledge on the current pulse of oncology including FDA updates and breaking data with our Targeted Pulse Quiz.
Test your knowledge on the current pulse of oncology including FDA updates and breaking data with our Targeted Pulse Quiz.
REGN7075 shows promise in cold tumors, dilutable thiotepa is approved, and patritumab deruxtecan receives a complete response letter for EGFR-mutated NSCLC. We also cover observed predictors for polycythemia vera and fast tract designation for TUB-040 for the treatment of platinum-resistant ovarian cancer.
Switch maintenance therapy with paclitaxel plus ramucirumab consistently prolonged survival regardless of clinical or molecular subgroups in HER2-negative disease controlled, metastatic gastric cancer.